Compare ASMB & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | PAVS |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 45.1M |
| IPO Year | 2010 | 2019 |
| Metric | ASMB | PAVS |
|---|---|---|
| Price | $35.86 | $0.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | 131.0K | ★ 230.3M |
| Earning Date | 11-10-2025 | 08-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,191,000.00 | $12,416,127.00 |
| Revenue This Year | $42.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 31.30 | ★ 18037.91 |
| 52 Week Low | $7.75 | $0.03 |
| 52 Week High | $39.71 | $1.50 |
| Indicator | ASMB | PAVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 31.73 |
| Support Level | $35.05 | $0.03 |
| Resistance Level | $36.92 | $0.05 |
| Average True Range (ATR) | 1.83 | 0.12 |
| MACD | -0.33 | -0.03 |
| Stochastic Oscillator | 33.58 | 0.82 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.